Therapeutic antibody expression technology.
With the technological advances made during the past decade, antibodies now represent an important and growing class of biotherapeutics. With the potential new targets resulting from genomics and with methods now in place to make fully human antibodies, the potential of antibodies as valuable therapeutics in oncology, inflammation and cardiovascular disease can be fully realised. Systems to produce these antibodies as full-length molecules and as fragments include expression in both mammalian and bacterial cells grown in bioreactors and in transgenic organisms. Factors including molecular fidelity and the cost of goods are critical in evaluating expression systems. Mammalian cell culture and transgenic organisms show the greatest promise for the expression of full-length, recombinant human antibodies, and bacterial fermentation seems most favorable for the expression of antibody fragments.
Chadd
H E
HE
Department of Process Sciences, Abgenix Inc, 6701 Kaiser Drive, Fremont, CA 94555, USA. chadd_h@abgenix.com
Chamow
S M
SM
D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000627:therapeutic use; D019149:Bioreactors; D001709:Biotechnology; D018929:Cell Culture Techniques / Q000379:methods*; D005285:Fermentation; D006801:Humans; D007128:Immunoglobulin Fragments / Q000096:biosynthesis / Q000627:therapeutic use; D030781:Organisms, Genetically Modified; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007128:Immunoglobulin Fragments; D011994:Recombinant Proteins